9.66

2.55% 0.24

4 D Molecular Therapeutics Inc (FDMT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$9.42

Aprire:

$9.72

Volume 24 ore:

892.21K

Relative Volume:

1.15

Capitalizzazione di mercato:

$504.99M

Reddito:

$88.24M

Utile/perdita netta:

$-160.90M

Rapporto P/E:

-3.6259

EPS:

-2.6642

Flusso di cassa netto:

$-129.35M

1 W Prestazione:

+9.34%

1M Prestazione:

+15.48%

6M Prestazione:

+11.16%

1 anno Prestazione:

+136.19%

Intervallo 1D:

$9.45

$9.97

Intervallo di 1 settimana:

$8.548

$9.97

Portata 52W:

$3.68

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Nome

4 D Molecular Therapeutics Inc

Settore

Healthcare (1104)

Industria

Biotechnology (617)

Telefono

(510) 505-2680

Indirizzo

5858 HORTON STREET #455, EMERYVILLE

Dipendente

196

Cinguettio

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

FDMT's Discussions on Twitter

Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FDMT 4 D Molecular Therapeutics Inc	9.66	504.99M	88.24M	-160.90M	-129.35M	-2.6642
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2025-11-07	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2025-01-13	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-11-21	Iniziato	Morgan Stanley	Underweight
2024-09-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2024-04-15	Iniziato	Barclays	Overweight
2024-02-07	Ripresa	Goldman	Buy
2023-10-26	Iniziato	RBC Capital Mkts	Outperform
2023-10-24	Iniziato	Cantor Fitzgerald	Overweight
2023-10-18	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-07-05	Iniziato	Chardan Capital Markets	Buy
2023-01-30	Iniziato	BMO Capital Markets	Outperform
2022-11-18	Iniziato	H.C. Wainwright	Buy
2022-11-15	Aggiornamento	Goldman	Neutral → Buy
2022-08-12	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Iniziato	Jefferies	Buy
2022-01-04	Iniziato	SVB Leerink	Outperform
2021-01-05	Iniziato	BofA Securities	Buy
2021-01-05	Iniziato	Evercore ISI	Outperform
2021-01-05	Iniziato	Goldman	Neutral

Mostra tutto

4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie

Jun 18, 2026

4D Molecular Therapeutics (FDMT) director granted 50,000 stock options with CIC vesting - Stock Titan

Jun 18, 2026

4D Molecular (NASDAQ: FDMT) grants director 50,000 stock options - Stock Titan

Jun 18, 2026

4D Molecular Therapeutics (FDMT) director receives 50,000-share stock option grant - Stock Titan

Jun 18, 2026

4D Molecular (NASDAQ: FDMT) director gets 50,000 stock options grant - Stock Titan

Jun 18, 2026

4D Molecular Therapeutics (FDMT) grants director John F. Milligan 75,000 options - Stock Titan

Jun 18, 2026

4D Molecular (FDMT) grants director 50,000 stock options at $9.42 - Stock Titan

Jun 18, 2026

Director at 4D Molecular Therapeutics (NASDAQ: FDMT) receives 50,000 options - Stock Titan

Jun 18, 2026

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape - The Manila Times

Jun 18, 2026

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

Jun 18, 2026